skip to Main Content

KRAS Mutations Represent Important Target in Expanding Treatment of Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Although combination chemotherapy remains the standard frontline treatment for patients with localized or advanced pancreatic cancer, genetic mutations such as BRCA1/2 have started to shift the field toward more targeted therapies. KRAS mutations represent the most common genetic alterations for patients with pancreatic cancer and finding more viable treatments to target that pathway would serve as a major boost for a patient population with many unmet needs, according to Philip A. Philip, MD, PhD, FRCP.

“Combination chemotherapy remains the mainstay of treatment. That hasn’t changed, and it’s not going to change anytime soon, whether we’re talking about localized disease or advanced disease,” Philip said. “However, exploiting DNA repair defects in the form of BRCA1/2 mutations is now an established form of treatment, and we’re trying to expand that into other mutations.” Read more…


Back To Top